GNLX Projected Dividend Yield
Genelux Corp ( NASDAQ : GNLX )Genelux Corporation is a late clinical-stage biopharmaceutical company. Co. is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient's tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. 20 YEAR PERFORMANCE RESULTS |
GNLX Dividend History Detail GNLX Dividend News GNLX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |